Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations

Masamichi Fukuda, Shinsuke Shibata, Naoko Shibata, Kenta Hagihara, Hiromoto Yaguchi, Hiromi Osada, Nobuo Takahashi, Eri Kubo, Hiroshi SasakiDepartment of Ophthalmology, Kanazawa Medical University, Uchinada, JapanPurpose: To investigate the safety of five types of antiglaucoma prostaglandin analog o...

Full description

Bibliographic Details
Main Authors: Fukuda M, Shibata S, Shibata N, Hagihara K, Yaguchi H, Osada H, Takahashi N, Kubo E, Sasaki H
Format: Article
Language:English
Published: Dove Medical Press 2013-03-01
Series:Clinical Ophthalmology
Online Access:http://www.dovepress.com/safety-comparison-of-additives-in-antiglaucoma-prostaglandin-pg-analog-a12450
id doaj-3855b2f9298c4cd7a0932b2ee13b91da
record_format Article
spelling doaj-3855b2f9298c4cd7a0932b2ee13b91da2020-11-25T00:44:49ZengDove Medical PressClinical Ophthalmology1177-54671177-54832013-03-012013default515520Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulationsFukuda MShibata SShibata NHagihara KYaguchi HOsada HTakahashi NKubo ESasaki HMasamichi Fukuda, Shinsuke Shibata, Naoko Shibata, Kenta Hagihara, Hiromoto Yaguchi, Hiromi Osada, Nobuo Takahashi, Eri Kubo, Hiroshi SasakiDepartment of Ophthalmology, Kanazawa Medical University, Uchinada, JapanPurpose: To investigate the safety of five types of antiglaucoma prostaglandin analog ophthalmic formulations, and to clarify their differences in accordance with contained additives (preservatives and surface-active agents).Methods: The following five types of ophthalmic solutions and three types of additives were investigated: latanoprost (Xalatan®; latanoprost), tafluprost (Tapros®; tafluprost), bimatoprost (Lumigan®; bimatoprost), travoprost (Travatan®; travoprost), travoprost (Travatan Z®; travoprost-Z), benzalkonium chloride (BAK), polyoxyethylene hardening castor oil 40 (HCO-40), and polysorbate 80 (P-80). These experimental solutions were exposed to the cultured cells of a rabbit-derived corneal cell line for a certain time, and the exposure time causing 50% cell damage (CD50), indicated by the ratio of viable cells to total cells was calculated (in vitro). In addition, corneal resistance (CR) was measured and CR ratio (post-treatment CR/pretreatment CR × 100) was calculated (in vivo).Results: CD50 of each ophthalmic solution was the longest with tafluprost, followed by travoprost-Z, bimatoprost, travoprost, and latanoprost. CD50 of 0.005%, 0.01%, and 0.02% BAK was 14.5 minutes, 8.1 minutes, and 4.0 minutes, respectively. The number of viable cells decreased to 60%, 8 minutes after exposure with HCO-40, and 30 minutes after being exposed to P-80. The CR ratio was 81.0% with travoprost and 82.0% with latanoprost, indicating a significant posttreatment reduction of CR (P < 0.05). The CR ratio did not decrease after treatment with tafluprost, travoprost-Z, or bimatoprost. The CR ratio of 0.005%, 0.01%, and 0.02% BAK was 105.0%, 90.5%, and 68.7%, respectively, and that of HCO-40 and P-80 was 108.7% and 114.2%, respectively.Conclusion: BAK, HCO-40, and P-80 were thought to be involved in corneal injuries caused by each ophthalmic solution. Corneal injuries due to surface action were observed when using HCO-40 and P-80. When HCO-40 was combined with BAK, it induced micellar BAK and reduced corneal injuries by BAK.Keywords: corneal resistance measuring device, additives, prostaglandin analogs, surface-active agents, corneal epithelial injuryhttp://www.dovepress.com/safety-comparison-of-additives-in-antiglaucoma-prostaglandin-pg-analog-a12450
collection DOAJ
language English
format Article
sources DOAJ
author Fukuda M
Shibata S
Shibata N
Hagihara K
Yaguchi H
Osada H
Takahashi N
Kubo E
Sasaki H
spellingShingle Fukuda M
Shibata S
Shibata N
Hagihara K
Yaguchi H
Osada H
Takahashi N
Kubo E
Sasaki H
Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations
Clinical Ophthalmology
author_facet Fukuda M
Shibata S
Shibata N
Hagihara K
Yaguchi H
Osada H
Takahashi N
Kubo E
Sasaki H
author_sort Fukuda M
title Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations
title_short Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations
title_full Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations
title_fullStr Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations
title_full_unstemmed Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations
title_sort safety comparison of additives in antiglaucoma prostaglandin (pg) analog ophthalmic formulations
publisher Dove Medical Press
series Clinical Ophthalmology
issn 1177-5467
1177-5483
publishDate 2013-03-01
description Masamichi Fukuda, Shinsuke Shibata, Naoko Shibata, Kenta Hagihara, Hiromoto Yaguchi, Hiromi Osada, Nobuo Takahashi, Eri Kubo, Hiroshi SasakiDepartment of Ophthalmology, Kanazawa Medical University, Uchinada, JapanPurpose: To investigate the safety of five types of antiglaucoma prostaglandin analog ophthalmic formulations, and to clarify their differences in accordance with contained additives (preservatives and surface-active agents).Methods: The following five types of ophthalmic solutions and three types of additives were investigated: latanoprost (Xalatan®; latanoprost), tafluprost (Tapros®; tafluprost), bimatoprost (Lumigan®; bimatoprost), travoprost (Travatan®; travoprost), travoprost (Travatan Z®; travoprost-Z), benzalkonium chloride (BAK), polyoxyethylene hardening castor oil 40 (HCO-40), and polysorbate 80 (P-80). These experimental solutions were exposed to the cultured cells of a rabbit-derived corneal cell line for a certain time, and the exposure time causing 50% cell damage (CD50), indicated by the ratio of viable cells to total cells was calculated (in vitro). In addition, corneal resistance (CR) was measured and CR ratio (post-treatment CR/pretreatment CR × 100) was calculated (in vivo).Results: CD50 of each ophthalmic solution was the longest with tafluprost, followed by travoprost-Z, bimatoprost, travoprost, and latanoprost. CD50 of 0.005%, 0.01%, and 0.02% BAK was 14.5 minutes, 8.1 minutes, and 4.0 minutes, respectively. The number of viable cells decreased to 60%, 8 minutes after exposure with HCO-40, and 30 minutes after being exposed to P-80. The CR ratio was 81.0% with travoprost and 82.0% with latanoprost, indicating a significant posttreatment reduction of CR (P < 0.05). The CR ratio did not decrease after treatment with tafluprost, travoprost-Z, or bimatoprost. The CR ratio of 0.005%, 0.01%, and 0.02% BAK was 105.0%, 90.5%, and 68.7%, respectively, and that of HCO-40 and P-80 was 108.7% and 114.2%, respectively.Conclusion: BAK, HCO-40, and P-80 were thought to be involved in corneal injuries caused by each ophthalmic solution. Corneal injuries due to surface action were observed when using HCO-40 and P-80. When HCO-40 was combined with BAK, it induced micellar BAK and reduced corneal injuries by BAK.Keywords: corneal resistance measuring device, additives, prostaglandin analogs, surface-active agents, corneal epithelial injury
url http://www.dovepress.com/safety-comparison-of-additives-in-antiglaucoma-prostaglandin-pg-analog-a12450
work_keys_str_mv AT fukudam safetycomparisonofadditivesinantiglaucomaprostaglandinpganalogophthalmicformulations
AT shibatas safetycomparisonofadditivesinantiglaucomaprostaglandinpganalogophthalmicformulations
AT shibatan safetycomparisonofadditivesinantiglaucomaprostaglandinpganalogophthalmicformulations
AT hagiharak safetycomparisonofadditivesinantiglaucomaprostaglandinpganalogophthalmicformulations
AT yaguchih safetycomparisonofadditivesinantiglaucomaprostaglandinpganalogophthalmicformulations
AT osadah safetycomparisonofadditivesinantiglaucomaprostaglandinpganalogophthalmicformulations
AT takahashin safetycomparisonofadditivesinantiglaucomaprostaglandinpganalogophthalmicformulations
AT kuboe safetycomparisonofadditivesinantiglaucomaprostaglandinpganalogophthalmicformulations
AT sasakih safetycomparisonofadditivesinantiglaucomaprostaglandinpganalogophthalmicformulations
_version_ 1725273193829105664